OrbiMed’s Medicines Co MDCO Stock Holding History

OrbiMed’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-151,515	Closed	-$5.53M	–	146
2019 Q2	$5.53M	Buy	+151,515	New	+$4.95M	0.09%	108
2019 Q1	–	Sell	-54,600	Closed	-$1.04M	–	152
2018 Q4	$1.04M	Buy	+54,600	New	+$1.27M	0.02%	121

Other funds holding MDCO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

OrbiMed's MDCO Position: Q3 2019 in Review

OrbiMed sold out of Medicines Co (MDCO) in Q3 2019, closing a stake of 151,515 shares — an estimated $5.53M sold.

OrbiMed first reported a position in MDCO in Q4 2018 and held it in 2 quarters. The position peaked at $5.53M in Q2 2019. 250 funds tracked by Wall St. Rank hold MDCO as of Q3 2019.

OrbiMed reported no remaining Medicines Co position as of Q3 2019 after selling out during the quarter.
OrbiMed sold 151,515 Medicines Co shares in Q3 2019, an estimated $5.53M.
OrbiMed first reported a position in Medicines Co in Q4 2018 and held it in 2 quarters.
OrbiMed's Medicines Co position peaked at $5.53M in Q2 2019.
250 funds tracked by Wall St. Rank held Medicines Co as of Q3 2019.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.